Acrobot secures £2.6m windfall:
This article was originally published in Clinica
Computer-assisted surgery specialists Acrobot has secured £2.6m ($5.3m) in its first round of financing, allowing the company to take its technology to market and develop new products. The financing, which came from London Technology Fund, PUK Ventures and Imperial Innovations Group, will be used for the full commercialisation of the company's planner and navigation technologies, and continue the development of its active constraint technology for robotic applications. Acrobot (London, UK) had previously developed the navigation system in collaboration with UK orthopaedic device manufacturer the Corin Group, with the aim of combining robotic technology into the latter's Cormet metal on metal hip resurfacing implant.
You may also be interested in...
A randomized COVID-19 study spanning the whole of the UK could help to bolster the UK’s reputation as a location for future clinical trials. It is also being seen partly as the result of the UK regulator's "decisive action" in fast-tracking trials for potential COVID-19 therapies.
Manufacturers of endoscopic equipment, biofeedback devices and thermometers were among those cited for regulatory violations in US FDA warning letters this week. A total of four device-related enforcement missives were released by the agency.
The biopharma industry has struggled to recruit patients into clinical trials that adequately reflect the diverse patient populations they hope to reach with new products. Failure to improve minority subgroup participation now will cost trial sponsors later.